➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Mallinckrodt
Johnson and Johnson
Merck
Medtronic

Last Updated: December 5, 2020

DrugPatentWatch Database Preview

Dalbavancin hydrochloride - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for dalbavancin hydrochloride and what is the scope of freedom to operate?

Dalbavancin hydrochloride is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dalbavancin hydrochloride has fifty-seven patent family members in twenty countries.

One supplier is listed for this compound.

Summary for dalbavancin hydrochloride
International Patents:57
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 1
Clinical Trials: 19
DailyMed Link:dalbavancin hydrochloride at DailyMed
Recent Clinical Trials for dalbavancin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wake Forest University Health SciencesPhase 4
Infectious Diseases Physicians, Inc.Phase 4
Johns Hopkins UniversityPhase 4

See all dalbavancin hydrochloride clinical trials

Pharmacology for dalbavancin hydrochloride

US Patents and Regulatory Information for dalbavancin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan DALVANCE dalbavancin hydrochloride POWDER;INTRAVENOUS 021883-001 May 23, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Dow
Moodys
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.